Search Result

Results for "

CBP/EP300

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Androgen Receptor (1) Apoptosis (7) Autophagy (1) BCL6 (2) c-Myc (1) CTLA-4 (1) Discoidin Domain Receptor (1) Drug Derivative (1) E3 Ligase Ligand-Linker Conjugates (3) Epigenetic Reader Domain (50) Fungal (1) HIF/HIF Prolyl-Hydroxylase (2) Histone Acetyltransferase (63) Histone Demethylase (1) IFNAR (1) IKZF Family (1) Interleukin Related (1) LAG-3 (1) Ligands for E3 Ligase (1) Ligands for Target Protein for PROTAC (9) Molecular Glues (3) NF-κB (1) PARP (1) PD-1/PD-L1 (1) PROTACs (18) Reference Standards (4) Sirtuin (1) STAT (1) STING (1) Target Protein Ligand-Linker Conjugates (1) VEGFR (1) Wnt (3) β-catenin (3)
By Research Areas:	Cancer (99) Cardiovascular Disease (1) Infection (1) Inflammation/Immunology (5) Metabolic Disease (1) Neurological Disease (5)

By Targets:

Androgen Receptor (1)

Apoptosis (7)

Autophagy (1)

BCL6 (2)

c-Myc (1)

CTLA-4 (1)

Discoidin Domain Receptor (1)

Drug Derivative (1)

E3 Ligase Ligand-Linker Conjugates (3)

Epigenetic Reader Domain (50)

Fungal (1)

HIF/HIF Prolyl-Hydroxylase (2)

Histone Acetyltransferase (63)

Histone Demethylase (1)

IFNAR (1)

IKZF Family (1)

Interleukin Related (1)

LAG-3 (1)

Ligands for E3 Ligase (1)

Ligands for Target Protein for PROTAC (9)

Molecular Glues (3)

NF-κB (1)

PARP (1)

PD-1/PD-L1 (1)

PROTACs (18)

Reference Standards (4)

Sirtuin (1)

STAT (1)

STING (1)

Target Protein Ligand-Linker Conjugates (1)

VEGFR (1)

Wnt (3)

β-catenin (3)

By Research Areas:

Cancer (99)

Cardiovascular Disease (1)

Infection (1)

Inflammation/Immunology (5)

Metabolic Disease (1)

Neurological Disease (5)

104

Inhibitors & Agonists

Peptides

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-107455

A-485 Maximum Cited Publications 99 Publications Verification	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
A-485, a chemical probe, is a potent and selective catalytic inhibitor of *p300/CBP* with IC₅₀s of 9.8 nM and 2.6 nM for *p300* and *CBP* histone acetyltransferase (HAT), respectively .

HY-111784

Inobrodib 10+ Cited Publications CCS1477	Epigenetic Reader Domain	Cancer
Inobrodib (CCS1477) is an orally active, potent, and selective inhibitor of the p300/CBP bromodomain. Inobrodib binds to p300 and CBP with K_d values of 1.3 and 1.7 nM, respectively, and with 170/130-fold selectivity compared with BRD4 with a K_d of 222 nM. CCS1477 inhibits cell proliferation in prostate cancer cell lines and decreases androgen receptor (AR)- and C-MYC-regulated gene expression .

HY-14428

ICG-001 60+ Cited Publications	β-catenin Apoptosis	Cancer
ICG-001 is an inhibitor of β-catenin/TCF mediated transcription. ICG-001 works by specifically binding to cyclic AMP response element-binding protein with an IC₅₀ of 3 μM. ICG-001 selectively blocks the β-catenin/CBP interaction without interfering with the β-catenin/p300 interaction.

HY-15826

SGC-CBP30 15+ Cited Publications	Epigenetic Reader Domain Histone Acetyltransferase	Inflammation/Immunology Cancer
SGC-CBP30, a chemical probe, is a potent and highly selective CBP/p300 bromodomain (K_ds of 21 nM and 32 nM for *CBP* and *p300, respectively) inhibitor, displaying 40-fold selectivity over the first bromodomain of BRD4 [BRD4(1)]* bound. SGC-CBP30 strongly reduces secretion of IL-17A in Th17 cells and has anti-inflammatory effects .

HY-138539

CBP/p300 ligand 2	Ligands for Target Protein for PROTAC	Cancer
CBP/p300 ligand 2 is a ligand for target protein for PROTAC of dCBP-1. dCBP-1 is a potent and selective heterobifunctional degrader of p300/CBP .

HY-100726

GNE-272 5 Publications Verification	Histone Acetyltransferase Epigenetic Reader Domain	Cancer
GNE-272 is a potent and selective *CBP/EP300* inhibitor with IC₅₀ values of 0.02, 0.03 and 13 μM for CBP, EP300 and BRD4, respectively. GNE-272 is also a selective in vivo probe for CBP/EP300 .

HY-136285

CPI-1612	Histone Acetyltransferase	Cancer
CPI-1612 is a highly potent, orally active EP300/CBP histone acetyltransferase (HAT) inhibitor with an IC₅₀ of 8.1 nM for EP300 HAT. CPI-1612 has an anticancer activity .

HY-158113

CBPD-409	Histone Acetyltransferase PROTACs	Cancer
CBPD-409 is an orally active PROTAC degrader for *CBP/p300, with DC₅₀* of 0.2–0.4 nM. CBPD-409 exhibits antiproliferative effects in AR+ prostate cancer cell lines VCaP, LNCaP and 22Rv1, with IC₅₀s of 1.2–2.0 nM. CBPD-409 exhibits antitumor efficacy (Red: CBP inhibitor GNE049 (HY-108435); Blue: CRBN/cullin 4A Thalidomide (HY-14658); Black: Linker) .

HY-138536

PROTAC CBP/P300 Degrader-1 1 Publications Verification	PROTACs Epigenetic Reader Domain	Cancer
PROTAC CBP/P300 Degrader-1 is a potent PROTAC CBP/P300 degrader. PROTAC CBP/P300 Degrader-1 potently inhibited cell viability of multiple cancer cell lines .

HY-100482

CPI-637 10+ Cited Publications	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
CPI-637 is a selective and potent *CBP/EP300* bromodomain inhibitor with IC₅₀ values of 0.03 μM, 0.051 μM and 11.0 μM for *CBP, EP300* and BRD4 BD-1, respectively, and an EC₅₀ of 0.3 μM for *CBP* .

HY-134582

dCBP-1 10+ Cited Publications	PROTACs Epigenetic Reader Domain	Cancer
dCBP-1 is a potent and selective heterobifunctional degrader of *p300/CBP* based on Cereblon ligand. dCBP-1 is exceptionally potent at killing multiple myeloma cells and ablates oncogenic enhancer activity driving MYC expression .

HY-111422

PLX51107 3 Publications Verification	Epigenetic Reader Domain	Cancer
PLX51107 is a potent and selective BET inhibitor, with K_ds of 1.6, 2.1, 1.7, and 5 nM for BD1 and 5.9, 6.2, 6.1, and 120 nM for BD2 of BRD2, BRD3, BRD4, and BRDT, respectively; PLX51107 also interacts with the bromodomains of CBP and EP300 (K_d, in the 100 nM range).

HY-19541

I-CBP112 5 Publications Verification	Histone Acetyltransferase Epigenetic Reader Domain	Cancer
I-CBP112, a chemical probe, is a specific and potent acetyl-lysine competitive protein-protein interaction inhibitor, that inhibits the *CBP/p300* bromodomains, enhances acetylation by p300.

HY-136938

NEO2734 4 Publications Verification EP31670	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
NEO2734 (EP31670) is an orally active dual *p300/CBP* and BET bromodomain selective inhibitor, with IC₅₀ values of <30 nM for both p300/CBP and BET bromodomains . NEO2734 is active in SPOP mutant and wild-type prostate cancer .

HY-124696

PU139 4 Publications Verification	Histone Acetyltransferase	Cancer
PU139 is a potent pan-histone acetyltransferase (HAT) inhibitor. PU139 blocks the HATs Gcn5, p300/CBP-associated factor (PCAF), CREB (cAMP response element-binding) protein (CBP) and p300 with IC₅₀s of 8.39, 9.74, 2.49 and 5.35 μM, respectively .

HY-128875

CBP/p300-IN-10	Histone Acetyltransferase	Cancer
CBP/p300-IN-10 is a highly potent histone acetyltransferase EP300 and CREBBP with IC₅₀ values of 26 nM and 39 nM, respectively. CBP/p300-IN-10 can be used to research anticancer .

HY-141546

Pocenbrodib	Histone Acetyltransferase	Cancer
Pocenbrodib is a *P300/CBP* inhibitor. Pocenbrodib blocks the function of *P300/CBP* and inhibits the acetylation of histones and non-histone proteins. Pocenbrodib may be used in research related to castration-resistant prostate cancer and other cancers .

HY-101125

L-Moses 2 Publications Verification L-45	Epigenetic Reader Domain	Cancer
L-Moses (L-45), a chemical probe, is the first potent, selective, and cell-active p300/CBP-associated factor (PCAF) bromodomain (Brd) inhibitor with a K_d of 126 nM .

HY-111420

CBP/p300-IN-1	Epigenetic Reader Domain	Cancer
CBP/p300-IN-1 is a *CBP/EP300* bromodomain inhibitor.

HY-161369

CBPD-268	PROTACs Histone Acetyltransferase	Cancer
CBPD-268 is a potent and orally active *CBP/p300* PROTAC degrader with an DC₅₀ value of ≤ 0.03 nM. CBPD-268 induces CBP/p300 degradation and inhibits cell growth. CBPD-268 shows antitumor activity. CBPD-268 has the potential for the research of AR-positive prostate cancer (Structure Note: Red, Androgen receptor degrader (HY-W248665A); Blue, CBP/p300 ligand (HY-161483); Black, Linker) .

HY-P10238

MYBMIM	Apoptosis	Cancer
MYBMIM is an inhibitor for assembly of the molecular *MYB:CBP/P300* complex. MYBMIM inhibits growth of leukemia cells .

HY-154984

JET-209	Histone Acetyltransferase PROTACs	Cancer
JET-209 is a potent CBP/p300 PROTAC degrader, with DC₅₀ values of 0.05 nM and 0.2 nM for *CBP* and *p300*. JET-209 demonstrates remarkable anti-tumor activity against various acute leukemia cell lines and effectively inhibits tumor growth in xenograft tumor models. JET-209 can be used for the study of acute leukemia .

HY-152241

DS-9300	Histone Acetyltransferase	Cancer
DS-9300 is a potent, orally active, selective EP300/CBP HAT inhibitor with an IC₅₀ value of 28 nM. DS-9300 has anticancer activity and can be used in prostate cancer disease research .

HY-132197

CBP/p300-IN-12 1 Publications Verification	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
CBP/p300-IN-12 is a potent and selective covalent histone acetyltransferases p300 (IC₅₀ of 166 nM) and *CBP* inhibitor. CBP/p300-IN-12 decreases the levels of H3K27Ac of PC-3 cells (EC₅₀ of 37 nM). CBP/p300-IN-12 forms a covalent adduct with C1450 .

HY-136920

CBP/p300-IN-8 1 Publications Verification	Epigenetic Reader Domain	Cancer
CBP/p300-IN-8 is a potent inhibitor of the CBP/P300 family of bromodomains. CBP/p300-IN-8 inhibits CBP (IC₅₀=0.01-0.1 µΜ) and BRD4 (IC₅₀=1-1000 µΜ) activity .

HY-128876

CBP/p300-IN-3	Histone Acetyltransferase	Cancer
CBP/p300-IN-3, a p300/CBP histone acetyltransferase inhibitor, Compound 6, is sourced from patent WO 2019049061 A1 .

HY-173552

TCIP3	Molecular Glues Histone Acetyltransferase BCL6	Cancer
TCIP3 is a bivalent molecular glue with with dual binding to *p300/CBP* and BCL6. TCIP3 redirects p300 and CBP to activate programmed cell death genes normally repressed by the oncogenic driver, BCL6. TCIP3 can be used for the study of diffuse large B cell lymphomas (DLBCLs). TCIP3 exhibits no toxicity in non-transformed tonsillar lymphocytes or fibroblasts .

HY-112359

C-82	β-catenin Wnt	Cancer
C-82 is a second-generation specific *CBP/β-catenin* antagonist, which inhibits the binding between β-catenin and CBP and increases the binding between β-catenin and p300 .

HY-115539

Windorphen	Wnt β-catenin Histone Acetyltransferase	Cancer
Windorphen is a Wnt/β-catenin signal inhibitor that specifically targets the function of the c-terminal transactivation domain of β-catenin-1 but not β-catenin-2. Windorphen selectively targets *p300, disrupting the association of the mammalian β-catenin with p300* but not CBP .

HY-134591

Thalidomide-NH-PEG4-COOH	E3 Ligase Ligand-Linker Conjugates Autophagy Apoptosis	Cancer
Thalidomide-NH-PEG4-COOH is an E3 ligase ligand-linker conjugate which can be used for synthesizing dCBP-1. dCBP-1 is a potent and selective heterobifunctional degrader of p300/CBP .

HY-160260

EP300/CBP-IN-1	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
EP300/CBP-IN-1 (compound 172) is a potent *EP300/CBP* inhibitor with IC₅₀s of 2.3 nM and 2.1 nM for CBP BRD and EP300 BRD, respectively. EP300/CBP-IN-1 has the inhibitory effect on the proliferation of prostate cancer CWR22RV1 cells .

HY-139108

DCH36_06	Histone Acetyltransferase Apoptosis	Cancer
DCH36_06 is a potent and selective *p300/CBP* inhibitor with IC₅₀s of 0.6 μM and 3.2 μM for *p300* and *CBP, respectively. DCH36_06 mediated p300/CBP* inhibition leading to hypoacetylation on H3K18 in leukemic cells. Anti-tumor activity .

HY-139148

UMB298	Epigenetic Reader Domain	Cancer
UMB298 is a potent and selective *CBP/P300* bromodomain inhibitor .

HY-134592

Piperidine-GNE-049-N-Boc	Ligands for Target Protein for PROTAC	Cancer
Piperidine-GNE-049-N-Boc is a ligand for target protein for PROTAC of dCBP-1 (HY-134582). dCBP-1 is a potent and selective heterobifunctional degrader of p300/CBP .

HY-147261

B026	Histone Acetyltransferase	Cancer
B026 is a selective, potent, orally active p300/CBP histone acetyltransferase (HAT) inhibitor with IC₅₀ values of 1.8 nM and 9.5 nM for p300 and CBP enzyme, respectively. B026 has anticancer activity for androgen receptor-positive (AR+) prostate cancer cell lines .

HY-110263

EML 425 2 Publications Verification	Histone Acetyltransferase Epigenetic Reader Domain	Cardiovascular Disease Neurological Disease Metabolic Disease
EML425 is a potent and selective CREB binding protein (CBP)/p300 inhibitor with IC₅₀s of 2.9 and 1.1 μM, respectively.

HY-162259

QC-182	PROTACs Histone Acetyltransferase	Cancer
QC-182 is a potent PROTAC degrader of *p300/CBP. QC-182 reduces p300* protein in the SK-HEP-1 cells (DC₅₀ = 93nM). QC-182 potently and effectively inhibits cell growth in the SK-HEP-1 and JHH7 cell lines with IC₅₀ values of 0.733 and 0.477 μM, respectively. QC-182 can be used for the research of hepatocellular carcinoma (HCC) .

HY-160261S

EP300/CBP-IN-2	Epigenetic Reader Domain	Cancer
EP300/CBP-IN-2 is a potent *EP300/CBP* inhibitor that has good activity in vivo. EP300/CBP-IN-2 can be used for the research of cancer .

HY-161959

EP300/CBP ligand 1	Ligands for Target Protein for PROTAC	Cancer
EP300/CBP ligand 1 is a PROTAC target protein ligand (Ligands for Target Protein for PROTACs). EP300/CBP ligand 1 can be used for synthesis dCE-2 (HY-161958) .

HY-161960

EP300/CBP ligand 2	Ligands for Target Protein for PROTAC Epigenetic Reader Domain	Cancer
EP300/CBP ligand 2 (compound S19) is a ligand targeting the bromodomain of CREB binding protein (CBP) and E1A-associated protein (EP300). EP300/CBP ligand 2 can be used as a target protein ligand in the PROTAC structure, and can be coupled to the E3 ubiquitin ligase ligand through the PTOTAC Linker to synthesize PROTAC molecules with degradation effects. For example, EP300/CBP ligand 2 can be coupled with the conjugate (E3 ubiquitin enzyme ligand + Linker) Thalidomide-NH-C10-Boc (HY-161961) to produce the PROTAC molecule dCE-2 (HY-161958) .

HY-164005

CBP/EP300 bromodomain receptor-IN-1	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
CBP/EP300 bromodomain receptor-IN-1 (Compound 10) is an inhibitor for CBP/EP300 bromodomain receptor, which binds to proteins having a bromodomain in nanomolar level .

HY-161483

CBP/p300 ligand 3	Epigenetic Reader Domain Histone Acetyltransferase	Neurological Disease Cancer
CBP/p300 ligand 3 is a target protein ligand of CBPD-268 (HY-161369). *CBP* and *p300* are two proteins with histone acetyltransferase (HAT) activity, and *CBP* and *p300* play key roles in regulating biological processes such as gene expression, cell proliferation, differentiation and DNA repair. Through its acetyltransferase activity, *CBP/p300* can acetylate histones and other proteins, thereby regulating chromatin structure and gene expression. CBP/p300 ligand 3 regulates the function of *CBP/p300* by binding to a specific domain of the *CBP/p300* protein (the bromine domain or HAT domain), inhibiting its enzyme activity or altering its interactions with other proteins (transcription factors). CBP/p300 ligand 3 can be used in cancer, neurodegenerative diseases and other disease models associated with abnormal *CBP/p300* function .

HY-139707

PROTAC CBP/P300 Degrader-3 Thalidomide-NH-CBP/p300 ligand 2	PROTACs Molecular Glues Epigenetic Reader Domain	Cancer
PROTAC CBP/P300 Degrader-3 (P-007) is a PROTAC-based CBP and p300 degrader (extracted from patent WO2020173440) .

HY-100132

CBP/p300-IN-5	Histone Acetyltransferase	Cancer
P300/CBP-IN-5 is a potent p300/CBP histone acetyltransferase inhibitor extracted from patent WO2016044770A1, Example 715, has an IC₅₀ of 18.8 nM .

HY-100697

TPOP146 3 Publications Verification	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
TPOP146 is a selective *CBP/P300* benzoxazepine bromodomain inhibitor with K_d values of 134 nM and 5.02 μM for CBP and BRD4.

HY-124722

OHM1	HIF/HIF Prolyl-Hydroxylase	Cancer
OHM1 is an analog of HIF1α CTAD that inhibits its binding with p300/CBP. OHM1 targets CH1 domain with an affinity of 0.53 μM .

HY-139861

CBP/p300-IN-14	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
CBP/p300-IN-14 is a potent inhibitor of *CBP/EP300* (lysine acetyltransferase) with an IC₅₀ of 3.3 nM (extracted from patent WO2021213521A1, compound 27) .

HY-161958

dCE-2	PROTACs Histone Acetyltransferase	Cancer
dCE-2 (compound 5) is a PROTAC targeting CREB binding protein (CBP) and E1A-associated protein (EP300), which was developed based on the crystal structure of bromodomain (BRD) inhibitors. dCE-2 is composed of E3 ubiquitin ligase ligand Thalidomide-4-OH (HY-103596) (blue part), PROTAC Linker tert-Butyl 11-aminoundecanoate (HY-130715) (black part) and PROTAC target protein ligand EP300/CBP ligand 2 (HY-161960) (red part), of which the target protein ligand activity control is EP300/CBP ligand 1 (HY-161959), and the conjugate of E3 ubiquitin ligase ligand + Linker is Thalidomide-NH-C10-Boc (HY-161961) ^{[1] ^.}

HY-147290

NSC 694623	Histone Acetyltransferase	Cancer
NSC 694623 is a potent histone acetyltransferase (HAT) inhibitor with an IC₅₀ value of 15.9 μM for recombinant HAT p300/CBP-associated factor (PCAF). NSC 694623 has antiproliferative activity against certain cancer cells. NSC 694623 can be used for researching anticancer .

HY-176251

CBP/p300-IN-22	Histone Acetyltransferase Epigenetic Reader Domain NF-κB	Inflammation/Immunology Cancer
CBP/p300-IN-22 is a selective *CBP/EP300-BRD* inhibitor with an IC₅₀ of 4 nM. CBP/p300-IN-22 is highly selective over BRD4(1). CBP/p300-IN-22 reduces TNF-α-induced cytokine expression and subsequent immune cell recruitment by inhibiting NF-κB signaling, and has anticancer activity. CBP/p300-IN-22 can be used for the research of rheumatoid arthritis (RA) and other TNF-α-mediated inflammatory conditions.

Cat. No.	Product Name	Target	Research Area

HY-P10238

MYBMIM	Apoptosis	Cancer
MYBMIM is an inhibitor for assembly of the molecular *MYB:CBP/P300* complex. MYBMIM inhibits growth of leukemia cells .

HY-P11829

ACTR-AD1 2L	Histone Acetyltransferase	Cancer
ACTR-AD1 2L is a ACTR-AD1 peptide. ACTR-AD1 2L inhibits *CBP/p300-NCOA3* complex formation, modulates gene transcription, inhibits CBP/p300 acetylase activity, reduces acetylation levels, and exhibits antiproliferative activity. ACTR-AD1 2L binds with stronger affinity to its target proteins than the wild-type peptide. ACTR-AD1 2L can be used for the research of breast cancer .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: